详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Message in hand: the application of CRISPRi, RNAi, and LncRNA in adenocarcinoma

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Cancer Research Institute, Guangdong Medical University, Dongguan 523808, China [2]Pathology Department, Guangdong Medical University, Dongguan 523808, China [3]Microbiology and Immunology Department, Guangdong Medical University, Dongguan 523808, China [4]Department of Traditional Chinese Medicine, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan 523713, China

出处：

DOI：

ISSN：

摘要：

Gene editing interference technology has been flourishing for more than 30 years. It has always been a common means to interfere with the expression of particular genes. Today it has shown a broad application prospect in clinical treatment, especially in adenocarcinoma treatment. In just a few years, the CRISPRi technology has attracted much z attention with its precise targeting and convenient operability significantly promoted the transformation from bench to bedside, and won the Nobel Prize in Chemistry 2020. In recent years, the importance of non-coding RNA has led LncRNA research to the center. At the same time, it also recalls the surprises obtained in laboratory and clinic research by RNAi technologies such as microRNA, siRNA, and shRNA at the beginning of the century. Therefore, this article focuses on CRISPRi, RNAi, and LncRNA to review their gene interference mechanisms currently expected to be translational research. Their applications and differences in adenocarcinoma research will also be described powerfully. It will provide a helpful reference for scientists to understand better and apply several RNA interference technologies.© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

第一作者：

第一作者机构： [1]Cancer Research Institute, Guangdong Medical University, Dongguan 523808, China [2]Pathology Department, Guangdong Medical University, Dongguan 523808, China

共同第一作者：

通讯作者：

通讯机构： [1]Cancer Research Institute, Guangdong Medical University, Dongguan 523808, China [2]Pathology Department, Guangdong Medical University, Dongguan 523808, China [3]Microbiology and Immunology Department, Guangdong Medical University, Dongguan 523808, China [4]Department of Traditional Chinese Medicine, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan 523713, China

推荐引用方式(GB/T 7714)：

APA：

MLA：